What smart money is saying about Novartis
2 funds in our archive have pitched Novartis — most recently Loomis Sayles Global Growth Fund in March 2025.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Get an email when a fund writes about it
Position history
Between Q4 2024 and Q2 2026, 1 fund letter reported a position in Novartis — 1 trimmed or exited.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 1 | 0 |
| Q1 2025 | 0 | 0 | 0 | 1 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Fund activity · 1 position · 1 move
- June 2026
“Nike was eliminated after a management change and earnings report suggested that the pace of its recovery was likely to be slower than expected. Novartis was eliminated as the stock traded at a premium valuation relative to its earnings prospects.”
Novartis
Also mentioned · 1
These funds discuss Novartis — as a competitor, benchmark or comparable — without disclosing a position in it.
- MentionedPershing SquareJune 2026
“Alcon Inc (Alcon) Alcon is the world’s leading ophthalmology company, with a dominant position in surgical vision, strong positions in vision care and contact lenses, and a small but promising pharmaceuticals business. It benefits from attractive long-term, mid-single-digit market growth supported by aging population demographics, rising global incomes, and improved access to healthcare. Alcon is the premier franchise in this industry, benefiting from a massive global installed base, strong brand affinity, and unrivaled commercial capabilities. The core of Alcon’s business is its dominant surgical vision franchise, supported by a 30,000-unit capital equipment installed base. This installed base anchors a highly attractive stream of high-margin recurring consumables revenue — a classic “razor / razor- blade” model — which in turn funds Alcon’s ability to field the industry’s largest sales, commercial, and research organizations, powering its innovation flywheel. While the company has grown earnings at an 8% compounded rate since its spin-out from Novartis in 2019, we believe that historical growth significantly understates Alcon’s potential.”
Novartis
Fund coverage · 2 theses
- Loomis Sayles Global Growth FundMarch 2025
Novartis is positioned for long-term growth due to robust sales, expanding operating margins, a strong management team, and a promising clinical pipeline, making its shares a compelling investment opportunity.
Read the full thesis - Artisan International Value StrategyDecember 2024
Novartis is poised for over 10% revenue and profit growth in 2024, yet its shares are undervalued at 13X forecasted earnings due to regulatory pressures and a shift in investor focus towards obesity drugs.
Read the full thesis
Read every full thesis on Novartis
Unlock all 2 theses — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→